Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
FineImmu logo — Creating future health with advanced cell therapy drugs and...

FineImmu

Creating future health with advanced cell therapy drugs and precision immunodiagnostic products.

Founded 2018 Seed Total: $90.00M Biopharma, Biotechnology +1

General Information

Company Name FineImmu
Founded Year 2018
Industries Biopharma, Biotechnology, Health Care
Funding Stage Seed
Social

Get notified when FineImmu moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About FineImmu

FineImmu, established in 2018, is a biopharmaceutical and biotechnology startup dedicated to revolutionizing healthcare with advanced cell therapy drugs and precision immunodiagnostic products. The company's slogan "Creating future health with advanced cell therapy drugs and precision immunodiagnostic products" encapsulates its mission. FineImmu's innovative drug specializes in forecasting the anti-tumor immune response of PD-1 and PD-L1, as well as the efficacy of immune checkpoint inhibitors like CTLA4. In August 3, 2022, the company secured a significant CNY90.00M in the Seed Round investment from prominent investors including Panacea Venture, Beijing Huafang Investment, Revel Ventures, and Yabao Investment. FineImmu's presence in Health Care, Biopharma, and Biotechnology industries positions it at the forefront of the rapidly evolving biotech landscape. For further details, the company can be contacted through phone or physical address.

Taxonomy: cell therapy, immunotherapy, precision medicine, immunodiagnostic, PD-1, PD-L1, immune checkpoint inhibitors, cancer therapy, drug development, biopharmaceuticals

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 4
Investor Investor Investor
•••• •••• 		03 Aug 2022

FineImmu Alternatives & Competitors

FineImmu vs
CytoImmune Therapeutics
CytoImmune Therapeutics United States

CytoImmune Therapeutics, LLC develops novel, coordinated immunotherapy solutions for patients.

31 employees
Biotechnology, Health and Wellness
Compare FineImmu vs CytoImmune Therapeutics
FineImmu vs
Smart Immune
Smart Immune France

Pioneering thymus-empowered T-cell platform to fight cancer and infection

Grant
35 employees
Biotechnology, Health Care
FineImmu vs
NKGen Biotech, Inc.
NKGen Biotech, Inc. United States

Maximizing immune integrity through the development of unique natural killer (NK) cell therapies.

54 employees

FAQ About FineImmu

Creating future health with advanced cell therapy drugs and precision immunodiagnostic products.
FineImmu was founded in 2018.
FineImmu operates in the following industries: Biopharma, Biotechnology, Health Care.
FineImmu has completed 1 funding round, raising a total of $90.00M. The latest funding stage is Seed.
Top alternatives and competitors to FineImmu include CytoImmune Therapeutics, Smart Immune, NKGen Biotech, Inc., ImmunoGenesis, Inc., Memgen, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
FineImmu and CytoImmune Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors FineImmu and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes